Ponholzer A, Madersbacher S
Department of Urology and Andrology, Donauspital, Vienna, Austria.
Int J Impot Res. 2007 Nov-Dec;19(6):544-50. doi: 10.1038/sj.ijir.3901578. Epub 2007 Jul 5.
Recent large-scale epidemiological studies have documented a strong association between lower urinary tract symptoms (LUTS) and erectile dysfunction (ED). This observation has two important scientific and clinical aspects: (i) to reveal the pathomechanism linking LUTS and ED and (ii) to consider this fact in the individual approach for diagnosis and management of these two disorders. The following hypotheses are under investigation to explain the relation between LUTS and ED: (i) an increased Rho-kinase activation, (ii) an alpha-adrenergic receptor imbalance, (iii) a decrease of NOS/NO in the endothelium, (iv) atherosclerosis affecting the small pelvis and (v) an autonomic hyperactivity, each affecting simultaneously bladder, prostate and penis. According to a recent randomized trial, sildenafil has a positive effect on LUTS yet not on uroflowmetry in men with LUTS and ED. Although further trials are mandatory, phosphodiesterase-5 inhibitors might play a role in the management of LUTS in the future. alpha-Blockers have no relevant effect on erectile function, tamsulosin leads to retrograde ejaculation in up to 10%. 5alpha-Reductase inhibitors are associated with ED, loss of libido and reduction of ejaculate volume in up to 10%. Transurethral and open prostatectomy induce retrograde ejaculation in up to 90% of patients while their impact on erectile function is still controversially discussed. Minimal invasive treatment options (laser prostatectomy, transurethral microwave thermotherapy) have a lower rate of retrograde ejaculation in the range of 20-70%. LUTS and ED are strongly linked although the exact mechanism is poorly understood. Men seeking for help for LUTS/benign prostatic hyperplasia should be assessed for different aspects of sexual dysfunction and informed regarding the impact of medication and surgery on sexual health.
近期大规模流行病学研究已证实下尿路症状(LUTS)与勃起功能障碍(ED)之间存在密切关联。这一观察结果具有两个重要的科学和临床意义:(i)揭示连接LUTS和ED的发病机制;(ii)在针对这两种疾病的个体诊断和管理方法中考虑这一事实。目前正在研究以下假设以解释LUTS与ED之间的关系:(i)Rho激酶激活增加;(ii)α-肾上腺素能受体失衡;(iii)内皮中一氧化氮合酶/一氧化氮(NOS/NO)减少;(iv)影响小骨盆的动脉粥样硬化;(v)自主神经功能亢进,每种情况均同时影响膀胱、前列腺和阴茎。根据最近一项随机试验,西地那非对LUTS患者的LUTS有积极作用,但对尿流率无影响。尽管还需要进一步试验,但磷酸二酯酶-5抑制剂未来可能在LUTS的管理中发挥作用。α受体阻滞剂对勃起功能无相关影响,坦索罗辛导致逆行射精的发生率高达10%。5α还原酶抑制剂与ED、性欲减退和射精量减少有关,发生率高达10%。经尿道前列腺切除术和开放性前列腺切除术在高达90%的患者中会导致逆行射精,而它们对勃起功能的影响仍存在争议。微创治疗方案(激光前列腺切除术、经尿道微波热疗)导致逆行射精的发生率较低,在20%-70%之间。LUTS和ED密切相关,尽管确切机制尚不清楚。寻求LUTS/良性前列腺增生治疗的男性应评估性功能障碍的不同方面,并告知其药物和手术对性健康的影响。